欧洲内分泌学会生长激素替代治疗安全性的共识解读——颅咽管瘤术后  

Interpretation of the European Endocrine Society Consensus on the safety of growth hormone replacement therapy-Postoperative craniopharyngioma

作　　者：余红 何庆[1] Yu Hong;He Qing(Department of Endocrinology and Metabolism,Tianjin Medical University General Hospital,Tianjin 300052,China)

机构地区：[1]天津医科大学总医院内分泌代谢科,天津300052

出　　处：《国际内分泌代谢杂志》2023年第3期274-277,共4页International Journal of Endocrinology and Metabolism

基　　金：天津市医学重点学科(专科)建设项目(TJYXZDXK-030A);天津市科技局重大专项(21ZXJBSY00060);天津市卫生健康委员会科技项目(ZC20210, RC20126)。

摘　　要：2022年, 欧洲内分泌学会更新了《在癌症、颅内肿瘤及垂体瘤幸存者中生长激素替代治疗的安全性:共识声明》, 共包含了15条国际关注的安全性问题和态度声明。在欧洲内分泌学会的支持下, 生长激素研究学会邀请了16个国家涵盖10个专业学会的55位专家组成国际专家小组, 讨论了癌症和颅内肿瘤患者生长激素替代安全性的问题, 并形成国际专家共识。In 2022,the European Society of Endocrinology updated Safety of growth hormone replacement in survivors of cancer and intracranial and pituitary tumours:a consensus statement,which includes 15 internationally recognized safety issues and attitude statements.With the support of the European Society of Endocrinology,the Growth Hormone Research Society(GRS)convened a workshop,where 55 international key opinion leaders from 16 countries representing 10 professional societies discussed the safety of growth hormone replacement in cancer and intracranial tumor patients and reached an international expert consensus.

关 键 词：颅咽管瘤 术后 生长激素缺乏症 生长激素替代 

分 类 号：R739.41[医药卫生—肿瘤]